Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Taurolidine-citrate-heparin catheter lock solution reduces staphylococcal bacteraemia rates in haemodialysis patients.

Murray EC, Deighan C, Geddes C, Thomson PC.

QJM. 2014 Dec;107(12):995-1000. doi: 10.1093/qjmed/hcu128. Epub 2014 Jun 16.

PMID:
24939191
2.

Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.

Betjes MG, van Agteren M.

Nephrol Dial Transplant. 2004 Jun;19(6):1546-51. Epub 2004 Feb 19.

PMID:
14993498
3.

Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis.

Solomon LR, Cheesbrough JS, Bhargava R, Mitsides N, Heap M, Green G, Diggle P.

Semin Dial. 2012 Mar-Apr;25(2):233-8. doi: 10.1111/j.1525-139X.2011.00951.x. Epub 2011 Sep 15.

PMID:
21916999
4.

Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.

Dümichen MJ, Seeger K, Lode HN, Kühl JS, Ebell W, Degenhardt P, Singer M, Geffers C, Querfeld U.

J Hosp Infect. 2012 Apr;80(4):304-9. doi: 10.1016/j.jhin.2012.01.003. Epub 2012 Feb 18.

PMID:
22342714
5.

A Taurolidine-Citrate-Heparin Lock Solution Effectively Eradicates Pathogens From the Catheter Biofilm in Hemodialysis Patients.

Zwiech R, Adelt M, Chrul S.

Am J Ther. 2016 Mar-Apr;23(2):e363-8. doi: 10.1097/MJT.0b013e31828d4610.

PMID:
23665885
6.

A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis.

Solomon LR, Cheesbrough JS, Ebah L, Al-Sayed T, Heap M, Millband N, Waterhouse D, Mitra S, Curry A, Saxena R, Bhat R, Schulz M, Diggle P.

Am J Kidney Dis. 2010 Jun;55(6):1060-8. doi: 10.1053/j.ajkd.2009.11.025. Epub 2010 Mar 6.

PMID:
20207458
7.

Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial.

Tribler S, Brandt CF, Petersen AH, Petersen JH, Fuglsang KA, Staun M, Broebech P, Moser CE, Jeppesen PB.

Am J Clin Nutr. 2017 Sep;106(3):839-848. doi: 10.3945/ajcn.117.158964. Epub 2017 Aug 9.

PMID:
28793993
8.

Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.

Handrup MM, Møller JK, Schrøder H.

Pediatr Blood Cancer. 2013 Aug;60(8):1292-8. doi: 10.1002/pbc.24482. Epub 2013 Feb 15.

PMID:
23417891
9.

Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin.

Handrup MM, Fuursted K, Funch P, Møller JK, Schrøder H.

APMIS. 2012 Oct;120(10):794-801. doi: 10.1111/j.1600-0463.2012.02910.x. Epub 2012 May 15.

PMID:
22958287
11.
12.

Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia.

Winnett G, Nolan J, Miller M, Ashman N.

Nephrol Dial Transplant. 2008 Nov;23(11):3592-8. doi: 10.1093/ndt/gfn299. Epub 2008 May 25.

PMID:
18503094
13.

Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials.

Zhao Y, Li Z, Zhang L, Yang J, Yang Y, Tang Y, Fu P.

Am J Kidney Dis. 2014 Mar;63(3):479-90. doi: 10.1053/j.ajkd.2013.08.016. Epub 2013 Oct 11. Review.

PMID:
24125729
14.

A new haemodialysis catheter-locking agent reduces infections in haemodialysis patients.

Taylor C, Cahill J, Gerrish M, Little J.

J Ren Care. 2008 Sep;34(3):116-20. doi: 10.1111/j.1755-6686.2008.00027.x.

PMID:
18786077
15.

Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients.

Moore CL, Besarab A, Ajluni M, Soi V, Peterson EL, Johnson LE, Zervos MJ, Adams E, Yee J.

Clin J Am Soc Nephrol. 2014 Jul;9(7):1232-9. doi: 10.2215/CJN.11291113. Epub 2014 Jun 26.

16.

[Tunnelled internal jugular vein catheters with taurolidine lock: an acceptable challenge to arterio-venous fistula in 70 years old haemodialyzed patients: a prospective pilot study].

Branger B, Reboul P, Prelipcean C, Noguera ME, Cariou S, Granolleras C, Vecina F, Zabadani B, Boubenider S, Rousseau P, Deshodt G, Ramperez P, Hory B, Picard E, Branchereau P, Fabbro-Peray P, Fourcade J.

Nephrol Ther. 2011 Jul;7(4):237-41. doi: 10.1016/j.nephro.2011.04.001. Epub 2011 May 23. French.

PMID:
21601549
17.
18.

Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients.

Fontseré N, Cardozo C, Donate J, Soriano A, Muros M, Pons M, Mensa J, Campistol JM, Navarro-González JF, Maduell F.

Antimicrob Agents Chemother. 2014 Jul;58(7):4180-4. doi: 10.1128/AAC.02421-14. Epub 2014 May 12.

19.

Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters.

Yon CK, Low CL.

Am J Health Syst Pharm. 2013 Jan 15;70(2):131-6. doi: 10.2146/ajhp120300.

PMID:
23292266
20.

Supplemental Content

Support Center